IL264664A - - Google Patents
Info
- Publication number
- IL264664A IL264664A IL26466419A IL26466419A IL264664A IL 264664 A IL264664 A IL 264664A IL 26466419 A IL26466419 A IL 26466419A IL 26466419 A IL26466419 A IL 26466419A IL 264664 A IL264664 A IL 264664A
- Authority
- IL
- Israel
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/133—Amines having hydroxy groups, e.g. sphingosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662377154P | 2016-08-19 | 2016-08-19 | |
| PCT/IB2017/001140 WO2018033792A2 (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL264664A true IL264664A (https=) | 2019-03-31 |
| IL264664B IL264664B (en) | 2022-11-01 |
| IL264664B2 IL264664B2 (en) | 2023-03-01 |
Family
ID=60935566
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297367A IL297367A (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
| IL264664A IL264664B2 (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical preparations and uses related to them |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL297367A IL297367A (en) | 2016-08-19 | 2017-08-18 | Ophthalmic pharmaceutical compositions and uses relating thereto |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9867810B1 (https=) |
| EP (2) | EP4190328A1 (https=) |
| JP (3) | JP7297308B2 (https=) |
| KR (2) | KR102472774B1 (https=) |
| CN (2) | CN116726006A (https=) |
| AU (2) | AU2017311636B2 (https=) |
| CA (1) | CA3031370A1 (https=) |
| ES (1) | ES2934790T3 (https=) |
| IL (2) | IL297367A (https=) |
| MX (2) | MX2019001877A (https=) |
| PL (1) | PL3500255T3 (https=) |
| PT (1) | PT3500255T (https=) |
| WO (1) | WO2018033792A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3302426A4 (en) | 2015-05-29 | 2018-12-05 | Sydnexis, Inc. | D2o stabilized pharmaceutical formulations |
| PT3500255T (pt) | 2016-08-19 | 2023-01-10 | Orasis Pharmaceuticals Ltd | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas |
| PL3681500T3 (pl) * | 2018-04-24 | 2022-08-01 | Allergan, Inc. | Zastosowanie chlorowodorku pilokarpiny w leczeniu starczowzroczności |
| US11077053B2 (en) | 2018-08-21 | 2021-08-03 | Allergan, Inc. | Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia |
| EP3866790A4 (en) | 2018-10-15 | 2022-08-03 | Ocuphire Pharma, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF GLAUCOMA AND RELATED DISEASES |
| JP7670945B2 (ja) | 2018-10-26 | 2025-05-01 | オーパス・ジェネティクス・インコーポレイテッド | 老眼、散瞳、および他の眼障害の治療のための方法および組成物 |
| CA3138510A1 (en) * | 2019-05-08 | 2020-11-12 | Harrow Ip, Llc | Pharmaceutical compositions for treating presbyopia and methods for fabricating thereof |
| MX2023002946A (es) * | 2020-09-11 | 2023-04-11 | Intratus Nevada Inc | Composiciones y metodos para tratar presbicia, hipermetropia, astigmatismo, estereopsis disminuida, y sensibilidad al contraste disminuida. |
| MX394625B (es) * | 2020-11-12 | 2025-03-24 | Cesar Alejandro Sanchez Galeana | Composicion oftalmologica sinergica en dosis de baja concentracion eficaz en la prevencion, control y erradicacion de la presbicia |
| US20240139166A1 (en) * | 2021-02-04 | 2024-05-02 | Sydnexis, Inc. | Ophthalmic compositions for presbyopia |
| CN115368310B (zh) | 2021-05-18 | 2025-06-27 | 奥库菲尔医药公司 | 合成甲磺酸酚妥拉明的方法 |
| WO2023052977A1 (en) * | 2021-09-29 | 2023-04-06 | Avaca Pharma Private Limited | Compositions, methods and uses thereof |
| US11857538B2 (en) | 2022-01-14 | 2024-01-02 | Somerset Therapeutics, Llc | Stable pilocarpine formulations with modified buffer characteristics and related methods |
| US20250154135A1 (en) * | 2022-01-29 | 2025-05-15 | Nanjing Gritpharma Co., Ltd. | M-choline receptor agonist compound, preparation method therefor and use thereof |
| US12156868B2 (en) | 2022-02-09 | 2024-12-03 | Somerset Therapeutics, Llc | Formulations of pilocarpine and brimonidine compounds and related methods |
| CN117414333A (zh) * | 2023-11-30 | 2024-01-19 | 南京正科医药股份有限公司 | 盐酸毛果芸香碱滴眼液及其制备方法 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4255415A (en) | 1978-11-22 | 1981-03-10 | Schering Corporation | Polyvinyl alcohol ophthalmic gel |
| IT1229075B (it) | 1985-04-05 | 1991-07-17 | Fidia Farmaceutici | Medicamenti per uso topico, ottenuti tramite l'impiego dell'acido ialuronico |
| US4851521A (en) | 1985-07-08 | 1989-07-25 | Fidia, S.P.A. | Esters of hyaluronic acid |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2064160C (en) | 1991-03-27 | 1998-08-11 | Paul J. T. Missel | Use of combinations of gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions |
| US5178635A (en) * | 1992-05-04 | 1993-01-12 | Allergan, Inc. | Method for determining amount of medication in an implantable device |
| US5744155A (en) | 1993-08-13 | 1998-04-28 | Friedman; Doron | Bioadhesive emulsion preparations for enhanced drug delivery |
| US5422116A (en) | 1994-02-18 | 1995-06-06 | Ciba-Geigy Corporation | Liquid ophthalmic sustained release delivery system |
| SE9401109D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Opthalmic composition II |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| US6309630B1 (en) * | 1994-05-24 | 2001-10-30 | Insite Vision Incorporated | Non-steroidal anti-inflammatory ophthalmic suspensions |
| US5698533A (en) | 1994-07-26 | 1997-12-16 | Kang; Meng-Che | Ophthalmic pharmaceutical composition |
| US5612027A (en) | 1995-04-18 | 1997-03-18 | Galin; Miles A. | Controlled release of miotic and mydriatic drugs in the anterior chamber |
| US5972326A (en) * | 1995-04-18 | 1999-10-26 | Galin; Miles A. | Controlled release of pharmaceuticals in the anterior chamber of the eye |
| TW389694B (en) | 1995-08-17 | 2000-05-11 | Novartis Ag | Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics |
| CA2193149C (en) * | 1995-12-22 | 2002-04-23 | David H. Donabedian | Cationic therapuetic agents and delivery systems |
| CA2248881A1 (en) | 1996-03-13 | 1997-09-18 | Annouk Rozier | Ophthalmological composition of the type which undergoes liquid-gel phase transition |
| WO1998051281A1 (en) | 1997-05-14 | 1998-11-19 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations with excellent redispersibility |
| US6265444B1 (en) | 1997-05-23 | 2001-07-24 | Insite Vision Incorporated | Ophthalmic composition |
| US6291466B1 (en) * | 1998-07-30 | 2001-09-18 | Allergan Sales, Inc. | Cholinergic agents in the treatment of presbyopia |
| US6383471B1 (en) | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
| SE0002211D0 (sv) | 2000-06-13 | 2000-06-13 | Synphora Ab | Methods and compositions for prevention of myopia |
| JP2004503601A (ja) | 2000-07-13 | 2004-02-05 | ファルマシア・コーポレーション | 眼のｃｏｘ−２媒介疾患の処置及び予防におけるｃｏｘ−２阻害剤の使用法 |
| PE20020146A1 (es) | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| US6605640B2 (en) | 2001-01-31 | 2003-08-12 | Gerard M. Nolan | Method of treating certain eye diseases |
| US6540990B2 (en) | 2000-09-22 | 2003-04-01 | Gerard M. Nolan | Physiological method of improving vision |
| US6273092B1 (en) | 2000-09-22 | 2001-08-14 | Gerard M. Nolan | Methods for treating various eye disorders |
| US20020160988A1 (en) | 2001-02-20 | 2002-10-31 | Israel Institute For Biological Research | Compounds co-inducing cholinergic up-regulation and inflammation down-regulation and uses thereof |
| US20040058926A1 (en) | 2001-05-04 | 2004-03-25 | Rebanta Bandyopadhyay | Method of using cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders |
| AR034371A1 (es) | 2001-06-08 | 2004-02-18 | Novartis Ag | Composiciones farmaceuticas |
| US20030018382A1 (en) | 2001-07-17 | 2003-01-23 | Pflugfelder Stephen C. | Process for improving vision |
| FR2834212B1 (fr) | 2001-12-27 | 2004-07-09 | Besins Int Belgique | Utilisation d'une poudre a liberation immediate dans des compositions pharmaceutiques et nutraceutiques |
| US20050208102A1 (en) | 2003-04-09 | 2005-09-22 | Schultz Clyde L | Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases |
| CA2839847C (en) * | 2003-06-13 | 2016-03-15 | Masood A. Chowhan | Ophthalmic compositions containing a synergistic combination of two polymers |
| EP1654002B2 (en) * | 2003-08-07 | 2014-01-29 | Allergan, Inc. | Compositions for delivery of therapeutics into the eyes |
| US20050119262A1 (en) | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| MXPA03011987A (es) | 2003-12-19 | 2005-06-23 | Osio Sancho Alberto | Metodo para el tratamiento de la presbicia induciendo cambios en el poder y fisiologia corneal. |
| EP1611879B1 (en) | 2004-07-02 | 2009-08-12 | Novagali Pharma SA | Use of emulsions for intra- and periocular injection |
| WO2006062875A1 (en) | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
| EP2070518A2 (en) * | 2006-07-25 | 2009-06-17 | Osmotica Corp. | Ophthalmic solutions |
| ES2329161T3 (es) * | 2006-12-18 | 2009-11-23 | Jorge Luis Benozzi | Composiciones oftalmicas de estimulantes parasimpaticos y antiinflamatorios para su uso en el tratamiento de la presbicia. |
| EP2094291A1 (en) * | 2006-12-21 | 2009-09-02 | Novo Nordisk A/S | Dimeric prolactin receptor ligands |
| BRPI0807065A2 (pt) | 2007-01-31 | 2017-03-21 | Allergan Inc | biomateriais novos para liberação de fármaco ocular e um método para fazer e usar os mesmos |
| WO2008130591A2 (en) | 2007-04-18 | 2008-10-30 | The Gi Company, Inc. | Using trefoil polypeptides to treat eye lesions associated with ophthalmic procedures |
| WO2008153746A1 (en) | 2007-05-24 | 2008-12-18 | Aciex Therapeutics, Inc. | Formulations and methods for treating dry eye |
| GB0724558D0 (en) | 2007-12-15 | 2008-01-30 | Sharma Anant | Optical correction |
| WO2010135731A1 (en) | 2009-05-22 | 2010-11-25 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| US8299079B2 (en) | 2009-05-22 | 2012-10-30 | Kaufman Herbert E | Preparations and methods for ameliorating or reducing presbyopia |
| WO2011079123A1 (en) | 2009-12-23 | 2011-06-30 | Alimera Sciences, Inc. | Method of reducing incidence of intraocular pressure associated with intraocular use of corticosteroids |
| UA113525C2 (xx) | 2011-09-20 | 2017-02-10 | Спосіб лікування пресбіопії | |
| US10507245B2 (en) | 2012-07-19 | 2019-12-17 | Luis Felipe Vejarano Restrepo | Ophthalmic formulation and method for ameliorating presbyopia |
| US9089562B2 (en) * | 2013-08-28 | 2015-07-28 | Presbyopia Therapies Llc | Compositions and methods for the treatment of presbyopia |
| US10064818B2 (en) * | 2013-08-28 | 2018-09-04 | Presbyopia Therapies, LLC | Compositions and methods for the treatment of presbyopia |
| ES2538551B1 (es) * | 2013-12-20 | 2016-01-13 | Eurocanarias Oftalmológica, Sl | Composición Oftálmica para la corrección de la presbicia |
| CN106456584A (zh) * | 2014-02-11 | 2017-02-22 | 阿拉西斯医药公司 | 用于矫正老视的药理学眼科用组合物和其施用 |
| PT3500255T (pt) * | 2016-08-19 | 2023-01-10 | Orasis Pharmaceuticals Ltd | Composições farmacêuticas oftálmicas e utilizações relacionadas com estas |
-
2017
- 2017-08-18 PT PT178411443T patent/PT3500255T/pt unknown
- 2017-08-18 PL PL17841144.3T patent/PL3500255T3/pl unknown
- 2017-08-18 US US15/680,967 patent/US9867810B1/en active Active
- 2017-08-18 CN CN202310735857.7A patent/CN116726006A/zh active Pending
- 2017-08-18 AU AU2017311636A patent/AU2017311636B2/en active Active
- 2017-08-18 EP EP22209890.7A patent/EP4190328A1/en active Pending
- 2017-08-18 CA CA3031370A patent/CA3031370A1/en active Pending
- 2017-08-18 ES ES17841144T patent/ES2934790T3/es active Active
- 2017-08-18 CN CN201780062092.8A patent/CN109803652A/zh active Pending
- 2017-08-18 JP JP2019508247A patent/JP7297308B2/ja active Active
- 2017-08-18 IL IL297367A patent/IL297367A/en unknown
- 2017-08-18 MX MX2019001877A patent/MX2019001877A/es unknown
- 2017-08-18 EP EP17841144.3A patent/EP3500255B1/en active Active
- 2017-08-18 IL IL264664A patent/IL264664B2/en unknown
- 2017-08-18 KR KR1020197007252A patent/KR102472774B1/ko active Active
- 2017-08-18 WO PCT/IB2017/001140 patent/WO2018033792A2/en not_active Ceased
- 2017-08-18 KR KR1020227041350A patent/KR102588499B1/ko active Active
- 2017-11-29 US US15/825,505 patent/US20180207136A1/en not_active Abandoned
-
2018
- 2018-07-10 US US16/032,044 patent/US10639297B2/en active Active
-
2019
- 2019-02-15 MX MX2023003124A patent/MX2023003124A/es unknown
-
2020
- 2020-03-26 US US16/831,535 patent/US11129812B2/en active Active
-
2021
- 2021-07-27 US US17/386,138 patent/US11974986B2/en active Active
-
2023
- 2023-06-07 JP JP2023093802A patent/JP7839560B2/ja active Active
- 2023-09-07 AU AU2023226732A patent/AU2023226732A1/en not_active Abandoned
-
2024
- 2024-11-15 US US18/949,157 patent/US20250268867A1/en active Pending
-
2025
- 2025-08-25 JP JP2025139461A patent/JP2025168426A/ja not_active Withdrawn